Medable

CASE STUDY

Building a scalable oncology engine in a dynamic market

30 COUNTRIES. MULTIPLE STUDIES. ONE SCALABLE ONCOLOGY MODEL.
MEDABLE PLATFORM SOLUTIONS USED: Scale, eConsent, parallel build
THERAPEUTIC AREA: Oncology

A top-10 global pharmaceutical company partnered with Medable to rapidly expand the number of oncology trials it could concurrently conduct.

Specifically, they wanted to establish a global oncology program, starting with multiple phase III studies across 30 countries and more than 600 clinical sites.

The sponsor needed a new foundational model that could deliver agility, consistency, and scale across its growing pipeline in order to adhere to a changing market and therapeutic area.

The challenge: Managing oncology's complexity

Sponsors conducting modern oncology trials are frequently faced with significant challenges:

- Multiple cohorts, cohort expansion, indication expansion, and combination therapies within a program of studies that **frequently cause sponsors to start over.**
- **Adaptive designs** requiring continuous amendments and cohort expansion.
- **A global footprint** with repeated site usage but inconsistent study experiences.
- **Lack of standardization** that leads to repeated delays due to study rebuilds, increased training burden that can lead to lack of compliance, and fragmented data that can cause endpoints to suffer.

At the same time, the organization faced mounting pressure to develop a competitive and cohesive strategy across its entire portfolio at an accelerated pace, and ensure the generation of high-quality data that could be effectively combined and leveraged across studies.

Key outcomes and impact

Beyond improvements in speed, the sponsor also realized meaningful operational and analytical benefits, including greater data consistency across studies, a reduction in site burden and associated training time which improved compliance, and an enhanced ability to analyze combination treatment data at scale.

To meet these demands, Medable created a standardized oncology delivery model, enabling parallel study builds, reusable processes, and coordinated global execution. This approach delivered measurable improvements across speed, scale, and operational efficiency:

Three Phase III studies built in parallel, delivered on time for IRB submission. This was the first time a sponsor was able to operationalize oncology at this scale in our industry

20 – 30% faster delivery timelines compared to standard approaches

600+ sites activated across 30 countries with a consistent and easy experience

Reusable packages created for future studies that accelerate program growth

How we did it: A scalable foundation for oncology delivery

Medable partnered with the sponsor to fundamentally redesign how oncology trials are built and delivered. Their approach was anchored by three core pillars.

Consistency through standardization

This approach reduced variability and eliminated the need to rebuild studies from scratch, ensuring that sites immediately recognized and understood how to run the sponsor's studies.

- Built a reusable digital library of instruments, workflows, and templates
- Standardized up to 70% of study components across the trials
- Enabled a consistent site and patient experience across studies

Agility through flexible study design

This approach allowed study teams to begin with small cohorts, such as six patients, and expand dynamically as safety and efficacy data evolved, while avoiding the delays typically associated with traditional rebuild cycles.

Easily modified treatment changes, such as treatment breaks, changes in treatment, and varying depend-ability on caretakers as needed office hours.

Medable's platform was purpose-built to support oncology complexity:

- Rapid configuration of adaptive and cohort-based study designs
- Ability to clone, adapt, and deploy scale cohorts without downtime and instead of rebuilding workflows from scratch
- Seamless management of protocol amendments

Scale through parallelization and global execution

This model enabled the sponsor to scale execution across its portfolio without increasing operational burden.

- Delivered multiple oncology studies in parallel, including build, quality engineering, and user acceptance testing
- This led to increased speed to deployment and eliminated duplicative work as these items were previously tested and vetted
- Supported global IRB submissions across 30 countries and 42 locales
- Leveraged shared templates for faster regulatory readiness

Partnerships and dedicated team standards

- A strong collaborative partnership built over the course of four years across 25 studies
- A strong emphasis on team standards derived from Medable's understanding of the client's needs and executed across processes and trial technologies

Conclusion

By combining agility, consistency, and scale, Medable enabled the sponsor to transform oncology trial delivery from a fragmented, study-by-study process into a repeatable, portfolio-level capability.

This approach not only accelerates development timelines but positions the sponsor to build a fully integrated oncology portfolio designed for the future of precision medicine.

If you'd like to speak to someone at Medable about your trial, please talk with one of our experts.

www.medable.com

Medable